Castle Biosciences Inc revenue
Castle Biosciences Inc's revenue was $344m in fiscal 2025, up 3.7% on the year before. Since fiscal 2018 ($22.8m) it has grown at a compound 47.4% a year. Over the last twelve months it was $357m.
Revenue history
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23 | 52 | 63 | 94 | 137 | 220 | 332 | 344 | 357 |
| Growth on the year before | — | +127.6% | +20.8% | +50.2% | +45.7% | +60.4% | +51.1% | +3.7% | — |
| Gross profit | 17 | 45 | 53 | 78 | 105 | 175 | 272 | 273 | 276 |
| Gross margin | 76.8% | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% | 77.3% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Dermatologic | $216M | 62.9% | ▼ 15.8% |
| Non Dermatologic | $128M | 37.1% | ▲ 70.3% |
From Castle Biosciences Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Castle Biosciences Inc | $357m | 3.2% | 28.7% |
| Fulgent Genetics, Inc. | $324m | 6.8% | 1.8% |
| Twist Bioscience Corp | $432m | 19.2% | 22.4% |
| Schrodinger, Inc. | $259m | 8.9% | 10.2% |
| Mesa Laboratories Inc | $250m | 3.0% | 4.4% |
| Veracyte, Inc. | $562m | 17.3% | 19.6% |
Compare with peers
- Fulgent Genetics, Inc. revenue
- Twist Bioscience Corp revenue
- Schrodinger, Inc. revenue
- Mesa Laboratories Inc revenue
- Veracyte, Inc. revenue
Head to head: CSTL vs FLGTCSTL vs TWSTCSTL vs SDGR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies